Related by context. All words. (Click for frequent words.) 77 PEG SN# 77 mertansine 76 alvespimycin 75 ENMD # 75 MAGE A3 ASCI 75 YONDELIS 75 Degarelix 75 MGd 75 paclitaxel Taxol ® 74 liposomal formulation 74 Phase Ib II 74 GRNVAC1 74 evaluating tivozanib 74 relapsed MM 74 Pertuzumab 73 huN# DM1 73 adecatumumab 73 paclitaxel Taxol R 73 Aflibercept 73 huC# DM4 73 EndoTAG TM -1 73 CIMZIA ™ 73 CBLC# 73 CYT# potent vascular disrupting 73 Trofex 73 Virulizin ® 73 Tarceva TM 73 INCB# [001] 72 Omacetaxine 72 OMP #M# 72 BRIM2 72 HuMax EGFr 72 novel VDA molecule 72 HuLuc# 72 AEG# 72 phase IIb trial 72 Solazed 72 Symadex 72 Panzem R NCD 72 Azedra 72 Xelox 72 indibulin 72 Bezielle 72 CCX# 72 Kahalalide F 72 Pemetrexed 72 multicenter Phase II 72 midstage clinical 72 targeted radiotherapeutic 72 preclinically 72 ZACTIMA 72 Aplidin R 72 standard chemotherapy regimen 72 pertuzumab 72 hA# 72 oral prodrug 72 HGS# 72 Temsirolimus 72 pegylated liposomal doxorubicin 72 PhG alpha 1 72 Onconase 72 Xcellerated T Cells 72 Panzem 72 Vitaxin 72 AQ4N 72 trastuzumab DM1 T DM1 72 trastuzumab DM1 72 goserelin 72 farletuzumab 71 oral ridaforolimus 71 metaglidasen 71 AAG geldanamycin analog 71 Alocrest 71 forodesine 71 ApoB SNALP 71 oral picoplatin 71 docetaxel Taxotere R 71 Phase Ib clinical 71 Proellex TM 71 Aplidin 71 novel peptide 71 MEK inhibitor 71 Phase IIb clinical trials 71 Exherin TM 71 GW# [003] 71 metastatic hormone refractory 71 SinuNase ™ 71 lumiliximab 71 gemcitabine Gemzar ® 71 AKT inhibitor 71 MYDICAR ® 71 Phase Ib study 71 concurrent chemoradiation 71 Phase #b/#a clinical 71 Velcade bortezomib 71 IMA# 71 intravesical infusion therapy 71 enzastaurin 71 PrevOnco ™ 71 Safinamide 71 CR# vcMMAE 71 PI3K/Akt pathway inhibitor 71 vidofludimus 71 ELACYT 71 Gleevec resistant 71 nucleotide analog 71 Cloretazine ® 71 antibody MAb 71 GVAX ® 71 corticosteroid dexamethasone 71 Androxal TM 71 microtubule inhibitor 71 CTAP# Capsules 71 KNS # 71 deforolimus 71 Quinamed 71 PDE4 inhibitor 71 Amrubicin 71 PD LID 71 Cloretazine 70 HQK 70 mapatumumab 70 Phase 1b clinical trials 70 BrachySil TM 70 trastuzumab emtansine T DM1 70 Allovectin 7 70 Ceplene/IL-2 70 neratinib 70 gemcitabine cisplatin 70 Phase IIIb clinical 70 PROCHYMAL 70 RhuDex ® 70 phase IIa clinical 70 IMC #B 70 HGS ETR2 70 Glufosfamide 70 cannabinor 70 midstage trials 70 p# biomarker 70 bortezomib Velcade 70 Aloxi injection 70 Sapacitabine 70 Triapine R 70 Xanafide 70 R#/MEM # 70 docetaxel Taxotere ® 70 investigational humanized monoclonal antibody 70 Vandetanib 70 depsipeptide 70 busulfan 70 EndoTAGTM 1 70 Dacogen decitabine 70 intradermal injections 70 liposomal doxorubicin 70 XmAb# 70 phase IIb clinical 70 gemcitabine carboplatin 70 vorinostat 70 demonstrated antitumor activity 70 elotuzumab 70 CIMZIA TM 70 pharmacokinetic PK study 70 Myocet 70 HGS ETR1 70 orally administered inhibitor 70 radiation sensitizer 70 PRT# 70 pan HDAC inhibitor 70 AeroLEF TM 70 ChronVac C R 70 PEGylated interferon 70 Enzastaurin 70 JAK inhibitor 70 ongoing Phase 1b 70 Proxinium TM 70 DAVANAT 70 samalizumab 70 accumulate preferentially 70 EZN 70 Tarvacin 70 ATL# [001] 70 riociguat 70 CEQ# 70 PROSTVAC VF 70 Litx 70 estramustine 70 thalidomide Thalomid 70 orally dosed 70 Sym# 70 IL# PE#QQR 70 teriflunomide 70 SAR# [004] 70 OncoVEX GM CSF 70 imetelstat 70 antiangiogenic activity 70 seliciclib CYC# 70 OncoVex 70 preclinical efficacy 70 Vaxfectin TM 70 rxRNA 70 gefitinib Iressa 70 cisplatin gemcitabine 70 omega interferon 70 GLP toxicology studies 69 docetaxel chemotherapy 69 CHAMPION PCI 69 trastuzumab Herceptin ® 69 sorafenib tablets 69 vinca alkaloid 69 HER2 positive metastatic breast 69 cilengitide 69 Trastuzumab 69 STRIDE PD 69 APOPTONE 69 ToGA 69 Vicinium TM 69 rhIGFBP 3 69 sitaxsentan 69 DEB# 69 oral deforolimus 69 budesonide foam 69 EndoTAG 69 VNP#M 69 iniparib BSI 69 Rigel R# 69 Imprime PGG 69 HuMax 69 Lenocta 69 telomerase therapeutic 69 talabostat 69 ganetespib 69 volociximab 69 rhIL 7 69 Traficet EN 69 PF # [002] 69 Blinatumomab 69 Bayer HealthCare Onyx Pharmaceuticals 69 mGluR2 NAM 69 cediranib 69 ACAPODENE 69 IMC A# 69 eniluracil 69 JAK inhibitors 69 Elvitegravir 69 plasma kallikrein inhibitor 69 vinorelbine tartrate 69 axitinib 69 fosbretabulin 69 TransVax TM 69 OvaRex R 69 proteasome inhibitor 69 LymphoStat B TM 69 HGS ETR1 mapatumumab 69 AEGR 69 adecatumumab MT# 69 chemotherapeutic regimen 69 CD# antibody [001] 69 telaprevir dosed 69 VitiGam 69 UVIDEM 69 CYC# 69 TBC# 69 mTOR inhibition 69 drug conjugate 69 Elotuzumab 69 Seliciclib 69 Zevalin R Ibritumomab 69 Davanat 69 NeuVax 69 Daclizumab 69 CCR5 mAb 69 milatuzumab 69 tanespimycin 69 IRX 2 69 pharmacodynamic PD 69 including eniluracil ADH 69 hormone agonist 69 bevacizumab Avastin ® 69 tesmilifene 69 EOquin TM 69 dacetuzumab 69 XL# SAR# 69 trastuzumab Herceptin R 69 doxorubicin cyclophosphamide 69 Oral NKTR 69 DepoVax 69 Gemzar ® 69 tubulin inhibitor 69 JVRS 69 TRAIL R2 69 nab paclitaxel 69 relapsed multiple myeloma 69 OncoVEX 69 Talotrexin 69 OvaRex ® MAb 69 PEGPH# 69 Irinotecan 69 CD# CEA 69 CRLX# 69 investigational immunotherapy 69 Taxotere docetaxel 69 reslizumab 69 Xeloda ® 69 pomalidomide 69 intranasal delivery 69 ixabepilone 69 Telatinib 69 lexidronam injection 69 PNP inhibitor 69 GRN#L 69 radiolabeled monoclonal antibody 69 erlotinib Tarceva ® 69 Nanobody 69 Annamycin 69 nalbuphine ER 69 atacicept 69 recurrent glioblastoma multiforme 69 Archexin 69 5 fluorouracil leucovorin 69 antiangiogenic 69 galiximab 69 Vidofludimus 69 Fludara ® 69 antiangiogenic agents 69 postoperative chemotherapy 69 EXPAREL TM 69 Natalizumab 69 Dapagliflozin 69 alpha folate receptor 69 TLK# 69 Pazopanib 69 docetaxel Taxotere 69 investigational monoclonal antibody 69 ara C 69 Hsp# Inhibitor 69 BRAF inhibitor 68 Intravenous CP 68 CD# expressing 68 PORxin TM platforms 68 TELINTRA 68 TKM ApoB 68 chimeric monoclonal antibody 68 phase Ib clinical 68 lenalidomide Revlimid R 68 Phase Ib clinical trials 68 Ozarelix 68 generation URAT1 inhibitor 68 sorafenib Nexavar ® 68 Angiocept 68 ARIKACE ™ 68 Zybrestat 68 pemetrexed Alimta 68 azacytidine 68 vitro cytotoxicity 68 zanolimumab 68 Zemplar Capsules 68 interferon gamma 1b 68 OHR/AVR# 68 viral kinetics 68 M1 muscarinic 68 INSPIRE Trial Phase III 68 orally bioavailable 68 Amplimexon 68 IFN α 68 RAV# 68 urocortin 2 68 dasatinib Sprycel 68 Hormone Refractory Prostate Cancer 68 cleavable linker 68 histone deacetylase HDAC inhibitor 68 Ocrelizumab 68 metastatic colorectal 68 Trastuzumab DM1 68 Guanilib 68 pharmacodynamic profiles 68 IMP# 68 acyclovir Lauriad R 68 interleukin IL -# 68 Fulvestrant 68 Platinol ® cisplatin 68 OMP #R# 68 azilsartan medoxomil 68 Tesetaxel 68 oxaliplatin Eloxatin 68 TACI Ig 68 ZOLINZA 68 solithromycin 68 Onco TCS 68 RLY# 68 luteinizing hormone releasing 68 nucleoside analog 68 nonsmall cell lung cancer 68 Dasatinib 68 Aurora kinase 68 gamma secretase inhibitor 68 Trofex TM 68 R roscovitine 68 Immunotherapeutic 68 Aurora kinase inhibitor 68 GAP #B# 68 Arikace 68 low dose cytarabine 68 lenalidomide dexamethasone 68 SNT MC# 68 ritonavir boosted 68 SIR Spheres 68 NPC 1C 68 ATL/TV# 68 EGFR HER2 68 immunoconjugate 68 FOLOTYN ® 68 NXL# 68 davunetide intranasal AL 68 IV Busulfex 68 investigational protease inhibitor 68 Deforolimus 68 DOS# 68 potent antiproliferative 68 Protexia ® 68 PORxin TM 68 mda 7 68 Atrasentan 68 PLK1 SNALP 68 ularitide 68 velafermin 68 Phase IIa trials 68 aflibercept VEGF Trap 68 refractory prostate cancer 68 Virulizin R 68 Tesmilifene 68 Targretin capsules 68 RhuDex R 68 brivanib 68 cyclophosphamide methotrexate 68 brivaracetam 68 Thalomid ® 68 GTC recombinant human 68 Lisofylline LSF 68 LUX Lung 68 pharmacodynamic effects 68 Phase 1a clinical 68 metastatic colorectal carcinoma 68 sapacitabine CYC# 68 OXi# 68 anti CD3 antibody 68 Pharmacodynamic 68 favorable pharmacokinetic profile 68 myelofibrosis polycythemia vera 68 protein tyrosine phosphatase 1B 68 EGS# 68 potent topoisomerase II 68 lorvotuzumab mertansine 68 LEUKINE 68 paclitaxel poliglumex 68 ALGRX 68 Ixempra 68 G#DT 68 sorafenib Nexavar 68 sargramostim 68 dose cohort 68 Talabostat 68 K ras mutations 68 Neupogen ® 68 Interferon alpha 68 GAMMAGARD 68 uricase 68 blinded randomized placebo controlled 68 CA4P 68 Azedra ™ 68 angiogenesis inhibitor 68 pharmacologically active isomer 68 Renal Cell Carcinoma RCC 68 BAY #-# 68 FOLFOX6 68 MVax 68 Voreloxin 68 VEGFR2 inhibitor 68 Nexavar sorafenib 68 antiangiogenic therapy 68 recurrent metastatic ovarian cancer 68 Mipomersen 68 Decitabine 68 leading oral taxane 68 Gliadel Wafer 68 MKC# MT 68 LB# [003] 68 PrevOnco 68 MORAb 68 BENICAR HCT 68 LymphoStat B belimumab 68 non nucleoside HCV 68 paclitaxel Taxol 68 therapeutic monoclonal antibody 68 immunotherapeutic agent 68 DermaVir Patch 68 DXL# 68 taxane refractory 68 BCR ABL inhibitor 68 antimetabolite 67 Phase #b/#a 67 Neulasta ® 67 CDK inhibitor 67 rituximab Rituxan 67 Sudhir Agrawal D.Phil 67 ADVANCE PD 67 GRN# 67 OncoGel 67 IIa trial 67 HER2 overexpression 67 tolevamer 67 CoFactor 67 IAP inhibitor 67 Azacitidine 67 BioNumerik 67 pharmacokinetic equivalence 67 targeted antifolate 67 tramiprosate Alzhemed TM 67 plasmid DNA vaccine 67 DermaVir 67 telaprevir VX 67 Asentar 67 Phase #b/#a trial 67 virus HCV protease inhibitor 67 ALN HPN 67 CD# monoclonal antibody 67 initiated Phase Ib 67 Curaxin CBLC# 67 #I TM# 67 Solazed TM 67 dose escalation clinical 67 Abiraterone acetate 67 non nucleoside inhibitor 67 rALLy clinical trial 67 sipuleucel T 67 Panzem NCD 67 Carfilzomib 67 HCD# [002] 67 Panzem R 67 Golimumab 67 agonistic human 67 evaluating satraplatin 67 ORENCIA R 67 Antiangiogenic 67 DiLA2 67 Bendamustine 67 Pivotal Phase 67 ancrod 67 oncolytic virus therapies 67 evaluating mipomersen 67 Phase IIB 67 alkylating agent 67 Exelixis XL# 67 EOquin TM phase 67 lesinurad 67 humanised monoclonal antibody 67 orthotopic model 67 Vicriviroc 67 aleglitazar 67 Epratuzumab 67 Prodarsan R 67 IGF 1R inhibitor 67 GMX# 67 Cethrin R 67 Evoltra ® 67 Personalized Immunotherapy 67 isatoribine 67 kidney urologic 67 antiproliferative effects 67 Chemophase 67 CINTREDEKIN BESUDOTOX 67 vivo potency 67 Axitinib 67 BZL# 67 immunotoxin 67 PANVAC VF 67 intratumoral injection 67 phase Ib 67 flavopiridol 67 HDL Selective Delipidation 67 cobiprostone 67 A3 adenosine receptor 67 Randomized Phase 67 gemcitabine Gemzar 67 hypoxia selective 67 glucagon receptor 67 CytoFabTM 67 Belerofon 67 BrachySil 67 Parathyroid Hormone 67 IgG1 monoclonal antibody 67 potent cytotoxic 67 Meets Primary Endpoint 67 TASKi3 67 ChronVac C ® 67 Phase 2a trial 67 paclitaxel cisplatin 67 R#/MEM 67 PKC# 67 receptor tyrosine kinase inhibitor 67 lintuzumab 67 metastatic malignant 67 PNT# 67 BRIM3 67 initiate Phase 1b 67 tumor specific antigen 67 recurrent glioma 67 antitumor efficacy 67 orally inhaled 67 refractory chronic lymphocytic 67 small molecule tyrosine 67 ISF# 67 HCV protease inhibitor 67 Genasense ® oblimersen 67 IgG1 antibody 67 lapatinib Tykerb 67 cathepsin K inhibitor 67 HuMax CD4 67 Selective Electrochemical Tumor Ablation 67 Gamunex C 67 Melphalan 67 Phase III Pivotal 67 NVA# 67 Platinol ® 67 anti CTLA 67 Tumor Response 67 PHX# 67 Pivotal Phase III 67 VELCADE melphalan 67 selective modulator 67 Allovectin 7 ® 67 Tykerb lapatinib 67 alemtuzumab Campath 67 Alfacell proprietary ribonuclease 67 selective androgen receptor modulator 67 Capesaris 67 TG# [003] 67 systemic RNAi therapeutic 67 ER CHOP 67 MKC# MKC# PP 67 Gleevec imatinib mesylate 67 CLORETAZINE TM VNP#M 67 albiglutide 67 IMiDs ® 67 ulimorelin 67 entinostat 67 REOLYSIN ® 67 anticancer compound 67 INCB# [003] 67 Hedgehog Pathway Inhibitor 67 PSN# [002] 67 Romidepsin 67 GLP1 agonist 67 triphendiol 67 MDS AML 67 aurora kinase 67 XOMA 3AB 67 ANAVEX #-# [001] 67 Kinoid 67 dexamethasone Decadron 67 Psoraxine R 67 Solorel TM 67 HDAC Inhibitor 67 BCIRG 67 PROSTVAC TM 67 oral salmon calcitonin 67 EOquin 67 CCR9 antagonist 67 antibody MT# 67 Combination REOLYSIN R 67 2 inhibitor CYT# 67 cyclophosphamide doxorubicin vincristine 67 motesanib diphosphate 67 Saforis 67 Tyrima 67 APTIVUS 67 Ceflatonin R 67 ISTODAX 67 inhibitor RG# 67 ZK EPO 67 lenalidomide Revlimid 67 pharmacokinetic interactions 67 herpetic keratitis 67 Vidaza azacitidine 67 histone deacetylase inhibitor 67 EndoTAG TM 67 proteasome inhibitor bortezomib 67 PRX# 67 Prostate AdenoCarcinoma Treatment 67 YONDELIS R 67 Pimavanserin 67 Azedra TM 67 oral antiviral 67 5alpha reductase 67 Randomized Phase II 67 PROSTASCINT R 67 Factor VIIa 67 sunitinib malate 67 recurrent NSCLC 67 thymalfasin 67 Cleviprex TM clevidipine 67 orally bioavailable mimics 67 Silodosin 67 Cardiotoxicity 67 CCR1 67 HuMax CD# 67 decitabine 67 KRN# 67 lintuzumab SGN 67 humanised antibody 67 hyaluronidase enzyme 67 FOLFOX chemotherapy 67 NADiA 67 Phase 2b Clinical Trial 67 LHRH 67 metastatic renal cell 67 novel immunotherapeutic 67 Thiovir 67 Epirubicin 67 hypoxia activated prodrug 67 temsirolimus 67 nonnucleoside reverse transcriptase inhibitors 67 HCV protease inhibitors 67 arsenic trioxide injection 67 selective inhibition 67 Nilotinib 67 Bafetinib 67 FOLFOX6 chemotherapy regimen 67 Bortezomib 67 pain palliation 67 ProSavin 67 Alkeran 67 phase IIb study 67 HuMax TAC 67 bortezomib Velcade R 67 SPRYCEL ® 67 LY# [003] 67 rFSH 67 CIMZIA TM certolizumab pegol 67 Folfox 67 Cytotoxic 67 MCSP respectively 67 hyperphenylalaninemia HPA due 67 Urocidin 67 assessing T DM1 67 cMET 67 novel therapeutic antibodies 67 EGFR TKI 67 Tiuxetan 67 trastuzumab Herceptin 67 dexpramipexole 67 sodium thiosulfate STS 67 confirmatory clinical 67 Serdolect ® 67 metastatic CRC 67 humanized monoclonal antibodies 67 custirsen 67 NP2 Enkephalin 67 Camptosar ® 67 zoledronate 67 iniparib 67 Apoptone 67 Posiphen 67 TKB# 66 maximally tolerated dose 66 synthetic retinoid 66 elacytarabine 66 generation antisense inhibitor 66 eTag assays 66 Spiegelmer ® 66 adalimumab Humira 66 Kinase Inhibitors 66 intravesical instillation 66 PEG Interferon lambda 66 PEGylated 66 bevirimat Study 66 Urocidin TM 66 chemotherapy FOLFOX 66 GRNOPC1 contains 66 humanized anti 66 carcinoma HCC 66 biliary tract cancer 66 Afatinib 66 Phase IIA 66 mouse xenograft models 66 Completes Patient Enrollment 66 mg kg BID 66 olaparib 66 trial evaluating PRX# 66 obatoclax 66 PEG IFN 66 Prodarsan ® 66 Omnitarg 66 daunorubicin 66 GVAX Pancreas Vaccine 66 Interferon beta 1a 66 Inhaled nitric oxide 66 Etoposide 66 xanthine oxidase inhibitor 66 sunitinib Sutent 66 HepDirect prodrug 66 Nanobody ® 66 TOCOSOL Camptothecin 66 SAR# [002] 66 BNC# 66 inhaled AAT 66 Rebif ® 66 epoetin alpha 66 radezolid 66 Prolongs Survival 66 Pegylated Interferon 66 TheraCIM 66 Arranon 66 Angiolix 66 PRTX 66 novel anticancer 66 lomitapide 66 resminostat 66 anti CD3 66 CCX# B 66 INGN 66 randomized controlled Phase 66 IMiDs R 66 Tanespimycin 66 TRO# 66 Neuvenge 66 Ibritumomab Tiuxetan 66 gemcitabine chemotherapy 66 StemEx 66 RSD# oral 66 MT#/MEDI-# 66 recombinant PSMA vaccine 66 Gemcitabine 66 treatment naive genotype 66 Zalypsis 66 mitoxantrone plus 66 pegylated interferon alpha 66 Nexavar ® 66 systemic antifungal 66 anti EGFR antibody 66 QT QTc 66 Pharmacokinetic parameters 66 biologic DMARD 66 rindopepimut 66 inhaled treprostinil 66 Angiotensin Converting Enzyme 66 Anavex #-# 66 DUROS 66 alpha#beta# integrin 66 5 HT2C receptor 66 systemically administered 66 refractory metastatic 66 papillary renal cell carcinoma 66 Abbokinase 66 angiotensin analog 66 NEUGENE 66 Cloretazine R VNP#M 66 GVAX 66 Tyrosine Kinase Inhibitor 66 lead Aganocide compound 66 ZFP TF 66 anti amnesic 66 NSABP B 66 subcutaneous SC 66 Civacir 66 adjuvant cisplatin 66 hepatoma 66 oral ghrelin agonist 66 immune modulatory 66 TEMODAL 66 Epidermal Growth Factor Receptor 66 Allovectin 7 R 66 ALN VSP Phase 66 novel topoisomerase 66 pegfilgrastim 66 BrachySil ™ 66 hormone LHRH antagonist 66 cytokine refractory 66 ZFN modified 66 Glypromate 66 Plicera 66 Dacogen injection 66 LHRH antagonists 66 Curaxin 66 PARP inhibitor 66 protein kinase inhibitor 66 generation purine nucleoside 66 tolerability pharmacokinetics 66 carboplatin paclitaxel 66 Teriflunomide 66 recurrent malignant glioma 66 Interferon Beta 66 multi kinase inhibitor 66 omacetaxine mepesuccinate 66 Anticalins ® 66 CDDO Im 66 Liposomal 66 KSP inhibitor 66 thetreatment 66 AERx ® 66 serum phosphate 66 tipifarnib 66 TORISEL 66 Aliskiren 66 GHRH 66 IMiDs 66 Apaziquone 66 PegIFN RBV 66 ONCASPAR 66 Genz # 66 receptor inhibitor 66 Aclidinium 66 PENNVAX B 66 Aptivus ® 66 IMGN# 66 trabectedin 66 relapsed refractory multiple myeloma 66 chemotherapeutic drug 66 proprietary polysaccharide 66 REGN# 66 ONCONASE R 66 antitumor effect 66 Cetuximab Erbitux 66 apoptosis inducer 66 HDAC inhibition 66 humanized monoclonal 66 Lixivaptan 66 Presents Preclinical 66 renoprotective 66 cancer immunotherapies 66 QuadraSphere 66 PTH analogue 66 telomerase inhibitor drug 66 alefacept 66 Trandolapril 66 Pralatrexate 66 MKC# 66 A1PI 66 motesanib 66 CD4 monoclonal antibody 66 5 FU leucovorin 66 HCV RESPOND 2 66 castrate resistant prostate cancer 66 HCV SPRINT 66 Aurora Kinase 66 Lubiprostone 66 MDV# 66 tarenflurbil 66 oral methylnaltrexone 66 vascular disrupting 66 Cloretazine R 66 LHRH antagonist 66 TNFerade TM 66 cisplatin vinorelbine 66 Novel Oral 66 seliciclib 66 temozolomide TMZ 66 zotarolimus 66 immunotherapeutic vaccine 66 pharmacodynamic properties 66 BEXXAR Therapeutic Regimen 66 Diamyd ® 66 Erlotinib 66 metastatic castration resistant 66 Monoclonal antibody 66 Ceflatonin 66 Pegasys peginterferon alfa 2a 66 fluoropyrimidine 66 schizophrenia CIAS 66 Xcytrin R 66 multicenter Phase III 66 inhibit metastasis 66 TKM PLK1 66 Thiarabine 66 Neoadjuvant 66 registrational Phase 66 TIMP 1 66 SUCCEED trial 66 atrasentan 66 Loramyc R 66 replicon 66 liposome encapsulated 66 intranasal formulation 66 placebo controlled clinical 66 TH# [003] 66 multitargeted 66 bazedoxifene conjugated estrogens 66 HAAH 66 oral antidiabetic 66 AVONEX ® 66 Leukine ® 66 subcutaneous PRO 66 Anti Tumor 66 baminercept 66 radiotherapeutic 66 Fibrillex TM 66 MNTX 66 somatostatin analog 66 nonsquamous 66 oral chemotherapeutic agent